STOCK TITAN

Spectral AI, Inc. - $MDAI STOCK NEWS

Welcome to our dedicated page for Spectral AI news (Ticker: $MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spectral AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spectral AI's position in the market.

Rhea-AI Summary

Spectral AI, Inc. (Nasdaq: MDAI) announced their Q1 2024 financial results, showcasing a $6.3 million Research & Development revenue, cash reserves of $10.2 million, and the deployment of DeepView AI®-Burn devices in the UK with expected commercial revenue in 2H 2024. The company plans further regulatory submissions in the US and UK for the DeepView™ System in 2024 and 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Spectral AI, Inc. (Nasdaq: MDAI) will be participating in the Sidoti Micro-Cap Virtual Investor Conference on May 8-9, 2024. The company focuses on AI for medical diagnostics in wound care. Interested parties can access the live presentation and webcast on the company's website. Registration for the event is free.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
conferences AI
-
Rhea-AI Summary

Spectral AI, Inc. (Nasdaq: MDAI) received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center for their UKCA Mark Attainment. The award recognizes the company's leadership in the Texas Manufacturing space and their dedication to innovation in wound care through DeepView™ technology. TMAC, associated with MEP-NIST, supports Texas manufacturers with business consulting, technology implementation, workforce development, and strategic planning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has scheduled its 2024 first quarter financial results release for May 7, 2024. The company specializes in AI for medical diagnostics in wound care, aiming for faster and more precise treatment decisions. Investors can join the conference call at 5:00 pm Eastern Time to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary
Spectral AI appoints Erich Spangenberg as CEO of its health care IP-focused subsidiary, Spectral IP, aiming to unlock additional value for MDAI shareholders through potential spin-off. Spangenberg's IP monetization expertise and investment plans highlight the company's strategic move towards IP-related opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. appoints Jeremiah A. Sparks as Chief Commercialization Officer to drive commercialization of DeepView, an innovative wound management solution. Sparks brings over 20 years of medical device marketing experience, including global marketing and business strategy. His track record includes successful market assessments, commercialization plans, and product launches at major companies like Johnson & Johnson and Allergan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.39%
Tags
management AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) expects its 2023 Research & Development revenue of $18.1 million to increase to $28.0 million in 2024. Commercialization for DeepView AI®-Burn indication in the UK is underway, with revenue expected in 2H 2024. The company plans additional regulatory submissions in the US and UK for DeepView™ System burn and diabetic foot ulcer indications. Spectral AI highlights progress in product development, clinical trials, and financial results, aiming for commercial revenue across multiple platforms within the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) secures a $30.0 million prepaid advance and standby equity purchase agreement to support commercialization and research activities. The agreement with a long-only investor includes a fixed conversion price of $3.16 and provides flexibility for additional draws. CEO Peter M. Carlson highlights the importance of this funding for strategic imperatives and commercialization initiatives, emphasizing recent milestones in the U.K. and the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.24%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a $1 million investment from its largest shareholder into its subsidiary Spectral IP, focusing on advancing intellectual property in the AI ecosystem. The investment aims to unlock additional value for shareholders and accelerate innovation in medical diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.66%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) will report financial results for Q4 and full year 2023 on March 27, 2024. The company focuses on AI medical diagnostics for wound care. Investors can join the conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.05%
Tags
Spectral AI, Inc.

Nasdaq:MDAI

MDAI Rankings

MDAI Stock Data

30.21M
7.40M
56.82%
16.31%
1.1%
Medical Devices
Healthcare
Link
United States of America
DALLAS